These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 4810236)

  • 1. Cytotoxic effects of leukocytes and plasma on primary cultures of ovarian carcinoma.
    Halbrecht I; Komlos L
    Obstet Gynecol; 1974 Feb; 43(2):268-75. PubMed ID: 4810236
    [No Abstract]   [Full Text] [Related]  

  • 2. Cytotoxic effects of various sera on primary cultures of placentas and ovarian tumors.
    Halbrecht I; Komlos L
    Obstet Gynecol; 1971 Oct; 38(4):594-8. PubMed ID: 4999734
    [No Abstract]   [Full Text] [Related]  

  • 3. Lymphocyte cytotoxicity against allogeneic cultured cells in gynecologic malignancy.
    Arata T; Momozaki F; Kazuta M; Yamamoto H; Sekiba K
    Acta Med Okayama; 1979 Jun; 33(3):197-204. PubMed ID: 158947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody cytotoxicity studies in ovarian and cervical malignancies.
    Disaia PJ; Nalick RH; Townsend DE
    Obstet Gynecol; 1973 Nov; 42(5):644-50. PubMed ID: 4796001
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunological aspects of gynecological malignancies.
    DiSaia PJ
    J Reprod Med; 1975 Jan; 14(1):17-20. PubMed ID: 1110478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Some immunological reactivity indices in ovarian and uterine neoplasms].
    Gorodilov VV; Kochetkova VA; Sokolova II; Lastochkina VI
    Vopr Onkol; 1974; 20(1):50-6. PubMed ID: 4612971
    [No Abstract]   [Full Text] [Related]  

  • 7. Lymphocytes isolated from the peritoneal fluid of women with advanced ovarian carcinoma differ significantly from autologous peripheral blood lymphocytes.
    Melioli G; Ferrari I; Casartelli G; Ragni N
    Gynecol Oncol; 1993 Mar; 48(3):301-7. PubMed ID: 8462898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Blood group frequencies in obstetric and gynecologic diseases].
    Balika IuD; Trepakov EA
    Akush Ginekol (Mosk); 1977 Dec; (12):45-7. PubMed ID: 564616
    [No Abstract]   [Full Text] [Related]  

  • 9. The association of RCAS1 serum concentration with the reversibility or irreversibility of the process of immune cytotoxic activity restriction during normal menstrual cycle, cancer relapse, and surgical treatment for various types of squamous cell carcinomas and adenocarcinomas.
    Dutsch-Wicherek M; Wicherek L
    Am J Reprod Immunol; 2008 Mar; 59(3):266-75. PubMed ID: 18275520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Study of humoral and cellular immunity in the course of ovarian carcinoma].
    Laghi V; Carella G; Burrai I; Sacco F; Margariti PA; Villani L; Benedetti Panici P
    Minerva Ginecol; 1979 Oct; 31(10):737-46. PubMed ID: 317512
    [No Abstract]   [Full Text] [Related]  

  • 11. A study on the serum pregnancy zone protein levels in pregnant women and patients with gynecological tumors.
    Teng H; Zhang WY; Zhu FQ
    Chin Med J (Engl); 1994 Dec; 107(12):910-4. PubMed ID: 7882729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphocyte cytotoxicity in the peritoneal cavity and blood of patients with ovarian cancer.
    Berek JS; Bast RC; Lichtenstein A; Hacker NF; Spina CA; Lagasse LD; Knapp RC; Zighelboim J
    Obstet Gynecol; 1984 Nov; 64(5):708-14. PubMed ID: 6493663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Humoral antitumor cytotoxins in the ascitic forms of malignant ovarian tumors].
    Kondrat'eva AF; Livshits MA
    Vopr Onkol; 1980; 26(12):80-4. PubMed ID: 7467224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The diagnostic significance of pancreatic secretory trypsin inhibitor (PSTI) in patients with gynecologic tumors].
    Inoue M; Inoue Y; Ueda G; Matsuda K; Ogawa M; Mori T
    Nihon Gan Chiryo Gakkai Shi; 1984 Dec; 19(10):2225-9. PubMed ID: 6533205
    [No Abstract]   [Full Text] [Related]  

  • 15. Possibility of immunodiagnosis in ovarian cancer.
    Chin Med J (Engl); 1978 May; 4(3):185-90. PubMed ID: 98299
    [No Abstract]   [Full Text] [Related]  

  • 16. [In vitro study of 6B11GM to induce cellular immunity in patients with ovarian carcinoma].
    Yang F; Qian H; Feng J
    Zhonghua Fu Chan Ke Za Zhi; 1999 Nov; 34(11):660-3. PubMed ID: 11479947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell-mediated cytotoxicity in vitro of human lymphocytes against a cervical cancer cell line.
    Mashiba H; Matsunaga K; Ueno M; Jimi S
    Gan; 1977 Feb; 68(1):53-8. PubMed ID: 558932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leukocyte alkaline phosphatase activity in women with genital tract tumors.
    Jedwab GA; David MP; Burstein Y; Soferman N
    Isr J Med Sci; 1974 Nov; 10(11):1430-3. PubMed ID: 4443219
    [No Abstract]   [Full Text] [Related]  

  • 19. Cytotoxic factor from peritoneal cells: site of action.
    Pincus WB; Spanis CW; Sintek DE
    J Reticuloendothel Soc; 1971 Jun; 9(6):552-67. PubMed ID: 4938954
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunofluorescence measurement of C1 inactivator (alpha 2 neuraminoglycoprotein) activity of the surface of human carcinoma cells.
    Osther K; Linnemann R
    Acta Pathol Microbiol Scand B Microbiol Immunol; 1973 Jun; 81(3):365-72. PubMed ID: 4360139
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.